Evidence map›Paper›PMID 33569794›Full record

ArticlePrenatal diagnosis2021

The impact of the emergence of COVID-19 on women's prenatal genetic testing decisions.

Ruth M Farrell, Madelyn Pierce, Christina Collart, Caitlin Craighead, Marissa Coleridge, Edward K Chien, Uma Perni, Richard Frankel, Angela Ranzini, Brownsyne Tucker Edmonds and 1 more

Abstract read
In one paragraph

Article in Prenatal diagnosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruth M FarrellOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-8258-8842
Madelyn PierceOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Christina CollartOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Caitlin CraigheadOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-1889-0200
Marissa ColeridgeOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Edward K ChienOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Uma PerniOB/GYN and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Richard FrankelCleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
Angela RanziniDepartment of OB/GYN, MetroHealth Medical Center, Cleveland, Ohio, USA.
Brownsyne Tucker EdmondsDepartment of OB/GYN, Indiana University, Indianapolis, Indiana, USA.
Susannah S RoseCenter for Patient Experience, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

Ensuring Patients' Informed Access to Noninvasive Prenatal TestingR01HG010092 · NHGRI · CLEVELAND CLINIC LERNER COM-CWRU · PI Ruth Farrell · 2017 to 2026
$5.9M
NHGRI NIH HHS R01 HG010092NHGRI NIH HHS R01HG010092
6 · The paper itself

Abstract

objectiveWe conducted a study to examine the impact of COVID on patients' access and utilization of prenatal genetic screens and diagnostic tests at the onset of the COVID-19 pandemic in the United States.

methodsWe conducted telephone interviews with 40 patients to examine how the pandemic affected prenatal genetic screening and diagnostic testing decisions during the initial months of the pandemic in the United States. An interview guide queried experiences with the ability to access information about prenatal genetic testing options and to utilize the tests when desired. Audio recordings were transcribed and coded using NVivo 12. Analysis was conducted using Grounded Theory.

resultsThe pandemic did not alter most participants' decisions to undergo prenatal genetic testing. Yet, it did impact how participants viewed the risks and benefits of testing and timing of testing. There was heightened anxiety among those who underwent testing, stemming from the risk of viral exposure and the fear of being alone if pregnancy loss or fetal abnormality was identified at the time of an ultrasound-based procedure.

conclusionThe pandemic may impact patients' access and utilization of prenatal genetic tests. More research is needed to determine how best to meet pregnant patients' decision-making needs during this time.

Indexed as

Decision MakingGenetic TestingAdultCOVID-19FemaleHumansPregnancyPrenatal CarePrenatal Diagnosis

Identifiers

PMID33569794
PMCPMC8014673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.